Taxol

(paclitaxel)

ApprovedSmall molecule

Paclitaxel is a chemotherapy drug used to treat various cancers including breast cancer, ovarian cancer, and lung cancer by stopping cancer cells from dividing and growing.[2] Taxol is currently approved and in use across 229 indications[4].[1]

Taxol is one of 1781 small molecule programs targeting Germ Cell Tumor. It is currently in Approved.

229

Indications

2,239

Total Trials

Active Trials

1,780

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

Germ Cell TumorTerminated

Ovarian CancerUnknown status

Uterine CancerTerminated

Esophageal Squamous Cell CarcinomaActive, not recruiting

Esophageal CancerCompleted

Cervical CancerActive, not recruiting

Endometrial CancerUnknown status

Non-Small Cell Lung CancerRecruiting

Solid TumorActive, not recruiting

Head and Neck CancerUnknown status

Germ Cell TumorPhase 3

Terminated

Ovarian CancerApproved

Unknown status

Uterine CancerPhase 3

Terminated

Esophageal Squamous Cell CarcinomaPhase 3

Active, not recruiting

Esophageal CancerPhase 3

Completed

Cervical CancerPhase 3

Active, not recruiting

Endometrial CancerPhase 3

Unknown status

Non-Small Cell Lung CancerPhase 3

Recruiting

Solid TumorPhase 2

Active, not recruiting

Head and Neck CancerPhase 2

Unknown status

Showing 10 of 228 indications

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Taxol

Adenocard

2 3

Voltaren

Novartis

Preclinical

1 4

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 5

Spravato

WWim Janssens

Preclinical

2 6

Tricor

JJagotec

Preclinical

1 7

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 8

Chantix

PPrism Pharmaceuticals

Preclinical

1 9

Nubain

AAultman Health Foundation

Preclinical

1 10

Rilvegostomig

AstraZeneca

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

Triple-Negative Breast Cancer

NCT02488967

Phase 2/3Recruiting

Gastric Cancer

NCT05427383

Phase 2Not yet recruiting

Breast Cancer

NCT05067530

Q1 2027

Phase 3Recruiting

Metastatic Urothelial Cancer

NCT05754853

Phase 3Active, not recruiting

Non-Small Cell Lung Cancer

NCT04379635

Q2 2027

Phase 2Recruiting

Endometrial Cancer

NCT06413992

Clinical

Trials by Indication[1]

Breast Cancer45 trials

A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer

Completed·JJapan Breast Cancer Research Group·Phase 3·NCT02514681·226 enrolled

A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers

Completed·MMerrimack Pharmaceuticals·Phase 1·NCT01209195·41 enrolled

Cyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a "Window of Opportunity" Study

Not yet recruiting·MMedical University of Gdansk·Phase 2·NCT05067530·126 enrolled

Show 42 more trials

A Study of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer (SABRE-B)

Terminated· Roche logo

Roche·Phase 2·NCT00434356·46 enrolled

Adjuvant High-Dose, Sequential Chemotherapy in Treating Patients With Resected Breast Cancer

Completed·YYale University·Phase 2·NCT00002679·89 enrolled

A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer

Completed· Roche logo

Roche·Phase 3·NCT03493854·500 enrolled

Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive Breast Cancer

Unknown status·XXijing Hospital·Phase 2·NCT03273595·100 enrolled

Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00050167·603 enrolled

Neoadjuvant Study With Chemotherapy, Lapatinib And Trastuzumab In Breast Cancer

Completed· GSK logo

GSK·Phase 2·NCT00429299·121 enrolled

Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer

Terminated·WWest German Study Group·Phase 2·NCT01891357·64 enrolled

Phase II Neoadjuvant in Inflammatory Breast Cancer

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00756470·15 enrolled

Efficacy and Safety Study of Trastuzumab and Paclitaxel Based Regimens to Treat HER2-positive Breast Cancer

Unknown status·ZZhimin Shao·Phase 2·NCT01428414·100 enrolled

Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01593020·54 enrolled

Monoclonal Antibody Therapy, Cyclosporine, and Paclitaxel in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer

Unknown status·UUniversity of California, Davis·Phase 1·NCT00009763

A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer

Active, not recruiting·NNational University Hospital, Singapore·Phase 1/2·NCT05275777·66 enrolled

Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer

Completed·UUS Oncology Research·Phase 2·NCT02187991·169 enrolled

Phase 1b/2 Study of U3-1287 in Combination With Trastuzumab Plus Paclitaxel in Newly Diagnosed Metastatic Breast Cancer (MBC)

Terminated· Daiichi Sankyo logo

Daiichi Sankyo·Phase 1/2·NCT01512199·29 enrolled

De-escalation of Neoadjuvant Treatment (Paclitaxel + HP) in Early HER2+ Breast Cancer

Active, not recruiting·NNational Medical Research Radiological Centre of the Ministry of Health of Russia·Phase 2·NCT07421141·186 enrolled

Neoadjuvant Epirubicin, Cyclophosphamide, and Paclitaxel With or Without Gemcitabine in Treating Women Who Are Undergoing Surgery for Early Breast Cancer

Unknown status·—·Phase 3·NCT00070278·800 enrolled

Adjuvant FEC Versus EP in Breast Cancer (MIG5)

Completed·IIRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy·Phase 3·NCT02450058·1,055 enrolled

Breast Cancer Treatment Based on Organ-like Culture

Unknown status·XXijing Hospital··NCT03925233·300 enrolled

Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Women With Metastatic Breast Cancer

Unknown status·SSt. Louis University·Phase 1/2·NCT00002628·50 enrolled

High-Dose Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Metastatic Breast Cancer

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT00003392·61 enrolled

Combination Chemotherapy in Treating Women With Breast Cancer Who Have Undergone Surgery

Unknown status·CCancer Research Campaign Clinical Trials Centre·Phase 3·NCT00039546

Phase I-II Study of Vorinostat, Paclitaxel, and Bevacizumab in Metastatic Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00368875·54 enrolled

Neoadjuvant or Adjuvant Epirubicin, Cyclophosphamide, and Paclitaxel in Treating Women With Stage I, Stage II, or Stage III Breast Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00072319

Paclitaxel Plus Monoclonal Antibody Therapy in Treating Women With Recurrent or Metastatic Breast Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00003539·50 enrolled

Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer

Completed·GG1 Therapeutics, Inc.·Phase 2·NCT05112536·24 enrolled

Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00119262·226 enrolled

Study In Women And Men With Metastatic Breast Cancer That Have Overexpression Of ErbB2

Completed· Novartis logo

Novartis·Phase 3·NCT00281658·444 enrolled

Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer

Recruiting·JJiangsu Alphamab Biopharmaceuticals Co., Ltd·Phase 1/2·NCT06942234·180 enrolled

A Single-arm, Prospective, Phase II Clinical Study of the Combination of Entinostat and Oral Paclitaxel in the Treatment of HR+HER2- Advanced Breast Cancer

Not yet recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07441486·50 enrolled

Lapatinib Combined With Paclitaxel For Patients With First-Line ErbB2-Amplified Metastatic Breast Cancer

Completed· GSK logo

GSK·Phase 2·NCT00356811·57 enrolled

Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy

Active, not recruiting·DDaehwa Pharmaceutical Co., Ltd.·Phase 2/3·NCT03315364·549 enrolled

Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer

Recruiting·SShanghai Yizhong Pharmaceutical Co., Ltd.·Phase 3·NCT06143553·168 enrolled

Neoadjuvant Chemotherapy With WH002 in Women With HER2-negative Breast Cancer

Completed·BBeijing Wehand-Bio Pharmaceutical Co., Ltd·Phase 1·NCT06513364·40 enrolled

A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer

Completed·SSCRI Development Innovations, LLC·Phase 3·NCT00789581·614 enrolled

A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2

Unknown status·RRemeGen Co., Ltd.·Phase 3·NCT04400695·366 enrolled

Oral Paclitaxel + Encequidar vs IV Paclitaxel in Treatment of HER2 Negative Metastatic Breast Cancer

Not yet recruiting·HHealth Hope Pharma·Phase 3·NCT06835400·340 enrolled

Assessing ImmunoResponse Post Eribulin: Eribulin and Immunogenicity in Advanced Breast Cancer

Unknown status·IInstitut fuer Frauengesundheit·Phase 4·NCT05033769·82 enrolled

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT03725059·1,240 enrolled

Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT04109066·521 enrolled

Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling

Unknown status·NNSABP Foundation Inc·Phase 2·NCT03412643·64 enrolled

Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer

Completed·JJapan Breast Cancer Research Group·Phase 2·NCT01989780·160 enrolled

Chemotherapy for Elderly Patients Diagnosed With Localized HER2 Positive Breast Cancer

Withdrawn·IInstituto do Cancer do Estado de São Paulo·N/A·NCT02102438

Non-Small Cell Lung Cancer26 trials

Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer

Completed·FFox Chase Cancer Center·Phase 2·NCT00043108·19 enrolled

Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer

Terminated·EEQRx International, Inc.·Phase 3·NCT05493501·8 enrolled

A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

Terminated· Roche logo

Roche·Phase 2·NCT04832854·50 enrolled

Show 23 more trials

An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT02041533·541 enrolled

S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Completed·SSWOG Cancer Research Network·Phase 2·NCT00661193·59 enrolled

M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)

Terminated· EMD Serono Research & Development Institute, Inc. logo

EMD Serono Research & Development Institute, Inc.·Phase 2·NCT03840902·153 enrolled

Combination Chemotherapy Followed by Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer

Completed·YYale University·Phase 2·NCT00003111·10 enrolled

Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00005806

Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated

Recruiting·IIntergroupe Francophone de Cancerologie Thoracique·Phase 3·NCT06908993·133 enrolled

A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer

Completed· Roche logo

Roche·Phase 2·NCT01519804·108 enrolled

Combination Chemotherapy Followed by Radiation Therapy With or Without Paclitaxel in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Unknown status·IIRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy·Phase 3·NCT00039039·300 enrolled

Comparison of Two Combination Chemotherapy Regimens in Treating Non-small Cell Lung Cancer

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00006004

Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 1/2·NCT00023673·63 enrolled

Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery

Unknown status·BBaptist Health South Florida·Phase 2·NCT00004253

Cediranib, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Completed·NNCIC Clinical Trials Group·Phase 3·NCT00795340·306 enrolled

Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Terminated·CCTI BioPharma·Phase 3·NCT00551733·450 enrolled

Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer

Completed· Amgen logo

Amgen·Phase 3·NCT01966003·642 enrolled

Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT01454102·472 enrolled

A Study of Bevacizumab Plus Carboplatin and Paclitaxel in Subjects With Advanced, Previously Untreated, Squamous Non-Small Cell Lung Cancer (BRIDGE)

Completed· Roche logo

Roche·Phase 2·NCT00318136·47 enrolled

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 1·NCT00032032·69 enrolled

Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer

Completed·HHiberCell, Inc.·Phase 2·NCT00874848·90 enrolled

Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)

Active, not recruiting· BeiGene logo

BeiGene·Phase 3·NCT04379635·453 enrolled

Combination Chemotherapy With Sildenafil Plus Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer

Completed·HHamamatsu University·Phase 2/3·NCT00752115·120 enrolled

Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer

Not yet recruiting·SShanghai Huaota Biopharmaceutical Co., Ltd.·Phase 3·NCT07360132·480 enrolled

Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

Completed· Eli Lilly logo

Eli Lilly·Phase 3·NCT00112294·755 enrolled

Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)

Unknown status·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT04203485·762 enrolled

Ovarian Cancer15 trials

Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer

Terminated·AAGO Research GmbH·Phase 3·NCT03690739·9 enrolled

A Multi-Institutional Phase II Study of Cyclophosphamide, Paclitaxel, Cisplatin With G-CSF for Patients With Newly Diagnosed Advanced Stage Ovarian Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00001426·66 enrolled

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

Completed·EEpicentRx, Inc.·Phase 2·NCT02489903·139 enrolled

Show 12 more trials

QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy

Withdrawn·IImmunityBio, Inc.·Phase 1/2·NCT03197584

A Phase 1b Study of Sevacizumab in Combination With Chemotherapy in Chinese Patients With Platinum-Resistant Recurrent Ovarian Cancer.

Unknown status· Jiangsu Simcere Pharmaceutical Co., Ltd. logo

Jiangsu Simcere Pharmaceutical Co., Ltd.·Phase 1·NCT03763123·48 enrolled

A Phase II Study of Interaction of Lovastatin and Paclitaxel For Patients With Refractory or Relapsed Ovarian Cancer

Terminated·UUniversity of Iowa·Phase 2·NCT00585052·11 enrolled

Paclitaxel, Cisplatin, and Topotecan With or Without Filgrastim in Treating Patients With Newly Diagnosed Stage III or Stage IV Epithelial Ovarian Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00002913·30 enrolled

BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT01121406·110 enrolled

Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer

Completed·GGynecologic Oncology Group·Phase 3·NCT00003322·384 enrolled

TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer

Terminated· Amgen logo

Amgen·Phase 3·NCT01493505·1,015 enrolled

Real-World Effectiveness of Bevacizumab Based on AURELIA in Platinum-resistant Recurrent Ovarian Cancer

Completed·YYonsei University··NCT03367182·50 enrolled

A Study of SHR-A1811 in Subjects With Ovarian Cancer

Recruiting·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT06828354·300 enrolled

A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian Cancer

Unknown status· Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 3·NCT05145218·405 enrolled

Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Completed·AAravive, Inc.·Phase 1·NCT03639246·53 enrolled

A Trial of Weekly Paclitaxel With Oncothermia and Weekly cisPlatin With Oncothermia in Patients With Recurrent or Persistent Ovarian Cancer

Completed·SSeoul National University Hospital·Phase 1·NCT02344095·12 enrolled

Cervical Cancer9 trials

NeoAdjuvant Chemotherapy Followed by Radical Hysterectomy (OP) Versus Primary Chemo-RADiation in Cervical Cancer FIGO Stage IB2 and IIB

Unknown status·—·Phase 3·NCT02422563·534 enrolled

Study of Weekly Paclitaxel and Cisplatin in FIGO IB2 and IIA2 Cervical Cancer Followed by Radical Hysterectomy

Unknown status·—·Phase 2·NCT02432365·64 enrolled

Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy With and Without Bevacizumab as First-Line Treatment of Subjects With Advanced Cervical Cancer (FERMATA)

Unknown status·BBiocad·Phase 3·NCT03912415·316 enrolled

Show 6 more trials

Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01281852·37 enrolled

Paclitaxel, Topotecan, and Cisplatin in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer

Completed·GGynecologic Oncology Group·Phase 2·NCT00276796·66 enrolled

A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer

Withdrawn· Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 2·NCT05998941

A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer

Recruiting·SShanghai Shengdi Pharmaceutical Co., Ltd·Phase 3·NCT07168200·720 enrolled

QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer

Unknown status· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 3·NCT05446883·498 enrolled

QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer

Terminated· Qilu Pharmaceutical Co., Ltd. logo

Qilu Pharmaceutical Co., Ltd.·Phase 2/3·NCT04864782·46 enrolled

Gastric Cancer7 trials

Lapatinib in Combination With Weekly Paclitaxel in Patients With ErbB2 Amplified Advanced Gastric Cancer

Completed· GSK logo

GSK·Phase 3·NCT00486954·273 enrolled

Assess the Efficacy of AZD8931 in Combination With Paclitaxel Versus Paclitaxel Alone in Patients With Gastric Cancer

Terminated· AstraZeneca logo

AstraZeneca·Phase 2·NCT01579578·39 enrolled

A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression

Unknown status·RRemeGen Co., Ltd.·Phase 3·NCT04714190·351 enrolled

Show 4 more trials

Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric Cancer

Recruiting·DDai, Guanghai·Phase 2·NCT07392346·68 enrolled

KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy

Recruiting·SShanghai JMT-Bio Inc.·Phase 2/3·NCT05427383·286 enrolled

S1+ Paclitaxel (IV&IP) + Bevacizumab (IP) Versus S1+Oxaliplatin as First-line Treatment in Gastric Cancer With Malignant Ascites

Unknown status·—·Phase 2·NCT03990103·66 enrolled

Tislelizumab Combined With Chemotherapy in the Cross-line Treatment of First-line Resistant Advanced Gastric Cancer

Unknown status·FFujian Cancer Hospital·Phase 2·NCT05751265·39 enrolled

62 more indications

Primary Peritoneal Cancer6 trials

Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Terminated· AbbVie logo

AbbVie·Phase 3·NCT02470585·1,140 enrolled

S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission

Completed·SSWOG Cancer Research Network·Phase 3·NCT00003120·308 enrolled

Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Completed·FFox Chase Cancer Center·Phase 2·NCT00003944·3 enrolled

Show 3 more trials

Paclitaxel and Ganetespib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Terminated·FFox Chase Cancer Center·Phase 1/2·NCT01962948·12 enrolled

Cisplatin Induction With Paclitaxel Consolidation for Stage III-IV Epithelial Ovarian and Primary Peritoneal Cancer

Completed·JJohn P. Fruehauf·Phase 2·NCT00314678·40 enrolled

Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT02272790·95 enrolled

Patients With Advanced Solid Tumors4 trials

Combination Chemotherapy Plus Oblimersen in Treating Patients With Advanced Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00054548·55 enrolled

TAK-659 and Paclitaxel in Treating Patients With Advanced Solid Tumors

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT03756818·52 enrolled

Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors

Completed·UUniversity of California, San Francisco·Phase 1·NCT00313599·28 enrolled

Show 1 more trial

Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors.

Recruiting·FFirst Affiliated Hospital of Zhejiang University·Phase 1·NCT04778839·98 enrolled

Endometrial Cancer4 trials

Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 3·NCT00006027

BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer

Not yet recruiting·BBioMimetix JV, LLC·Phase 1/2·NCT06620029·27 enrolled

Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.

Terminated· Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 2·NCT05481645·71 enrolled

Show 1 more trial

Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer

Recruiting·—·Phase 2·NCT06413992·117 enrolled

Triple-Negative Breast Cancer3 trials

Effect of Platinum-based Versus Non-platinum-based Neoadjuvant Chemotherapy in Triple-negative Breast Cancer

Unknown status·—·Phase 2·NCT05872412·82 enrolled

Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer

Active, not recruiting·NNRG Oncology·Phase 3·NCT02488967·782 enrolled

Apatinib Combined With Paclitaxel and Carbopatin Intensive Regimen in Neoadjuvant Therapy for Locally Advanced Triple-negative Breast Cancer

Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT03735082·29 enrolled

Lung Cancer3 trials

Tarceva Surgery for Resectable Stage IIIA(N2) and IIIB (T4 N2) Non-Small-Cell Lung Cancer

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00063258·5 enrolled

Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer

Completed·FFox Chase Cancer Center·Phase 2·NCT00021333·29 enrolled

Pharmacological Ascorbate for Lung Cancer

Completed·—·Phase 2·NCT02420314·55 enrolled

Head and Neck Cancer3 trials

Optimized Intensity Modulated Irradiation for Head and Neck Cancer

Completed·UUniversity of Michigan Rogel Cancer Center·N/A·NCT00580983·90 enrolled

Paclitaxel and Radiation Therapy Plus Chemoprotection With Amifostine in Treating Patients With Stage III or Stage IV Head and Neck Cancer

Completed·MMassachusetts General Hospital·Phase 1/2·NCT00003193·37 enrolled

Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00089297·74 enrolled

Squamous Cell Carcinoma3 trials

A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck

Not yet recruiting·UUniversity of Chicago·Phase 2·NCT07346196·90 enrolled

E10A for the Treatment of Squamous Cell Carcinoma of the Head and Neck

Unknown status·GGuangzhou Double Bioproducts Co., Ltd·Phase 3·NCT02630264·540 enrolled

Neoadjuvant Chemotherapy for Patients With Squamous Cell Carcinoma of the Penis

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00512096·30 enrolled

Advanced Solid Tumors2 trials

A Study to Evaluate the Effects of Pevonedistat on the Corrected QT (QTc) Interval in Participants With Advanced Solid Tumors

Completed· Takeda logo

Takeda·Phase 1·NCT03330106·68 enrolled

A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT03918278·222 enrolled

Gastroesophageal Junction Cancer2 trials

A Study of Gentuximab + Paclitaxel in Patients With Advanced Gastric or Gastroesophageal Junction Cancer

Unknown status· Changchun GeneScience Pharmaceutical Co., Ltd. logo

Changchun GeneScience Pharmaceutical Co., Ltd.·Phase 1/2·NCT04053205·76 enrolled

Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer

Recruiting·—·Phase 2·NCT04660760·116 enrolled

Adenocarcinoma2 trials

Paclitaxel Plus Capecitabine With Capecitabine Maintenance Treatment in Metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction

Unknown status·PPeking University·Phase 3·NCT01015339·320 enrolled

A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma

Unknown status· Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 3·NCT04385550·528 enrolled

Chemotherapy2 trials

A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors

Completed· AbbVie logo

AbbVie·Phase 1·NCT02033551·47 enrolled

Paclitaxel vs Paclitaxel + Cetuximab in Recurrent - Metastatic Head & Neck Carcinoma After Failure of a 1º Chemotherapy

Terminated·GGrupo Español de Tratamiento de Tumores de Cabeza y Cuello·Phase 2·NCT03887442·17 enrolled

Advanced Malignancies2 trials

Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT01015222·122 enrolled

Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Terminated· Incyte logo

Incyte·Phase 1/2·NCT02711137·137 enrolled

Esophageal Adenocarcinoma2 trials

Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma

Recruiting·UUNICANCER·Phase 2·NCT06846346·88 enrolled

MLN1117 in Combination With Docetaxel, Paclitaxel, and Other Investigational Anticancer Agents to Treat Participants With Gastric and Gastroesophageal Adenocarcinoma

Terminated· Takeda logo

Takeda·Phase 1·NCT02551055·32 enrolled

Melanoma2 trials

Paclitaxel and GM-CSF in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery

Suspended·UUniversity of Virginia·Phase 2·NCT00278122·42 enrolled

Sorafenib, Carboplatin, and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00329641·25 enrolled

Small Cell Lung Cancer2 trials

Cisplatin Plus Etoposide With or Without Paclitaxel in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 3·NCT00003299·587 enrolled

A Trial of Paclitaxel (Genexol®) and Cisplatin Versus Paclitaxel Loaded Polymeric Micelle (Genexol-PM®) and Cisplatin in Advanced Non Small Cell Lung Cancer

Completed·SSamyang Biopharmaceuticals Corporation·Phase 2·NCT01023347·276 enrolled

Cancer of the Esophagus2 trials

Combination Chemotherapy Plus Radiation Therapy With or Without Fluorouracil in Treating Patients With Cancer of the Esophagus or Stomach

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 2·NCT00009880

Celecoxib, Paclitaxel, and Carboplatin in Treating Patients With Cancer of the Esophagus

Completed·WWeill Medical College of Cornell University·Phase 2·NCT00066716·39 enrolled

Paclitaxel2 trials

Phase I Trial of Paclitaxel With Perifosine

Completed·AAEterna Zentaris·Phase 1·NCT00399126·24 enrolled

Trial of Afatinib in Combination With Weekly Paclitaxel in the Second Line Treatment

Withdrawn·—·Phase 2·NCT02274012

Esophageal Cancer2 trials

Radiotherapy With or Without Concurrent Chemotherapy for Limited Lymphatic Metastasis of Esophageal Cancer - 3JECROG P-02

Unknown status·CChinese Academy of Medical Sciences·Phase 3·NCT03308552·164 enrolled

CHFR Methylation Status Esophageal Cancer Study

Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT01372202·31 enrolled

Fallopian Tube Cancer2 trials

TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer

Completed· Amgen logo

Amgen·Phase 3·NCT01204749·919 enrolled

Trial on Trabectedin (ET-743) vs Clinician's Choice Chemotherapy in Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancers of BRCA Mutated or BRCAness Phenotype Patients

Completed·FFondazione Policlinico Universitario Agostino Gemelli IRCCS·Phase 3·NCT02903004·242 enrolled

Bladder Cancer2 trials

Cisplatin, Paclitaxel, and Gemcitabine in Treating Patients With Progressive Unresectable Regional or Metastatic Bladder Cancer

Unknown status·GGERCOR - Multidisciplinary Oncology Cooperative Group·Phase 2·NCT00006118

Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 1/2·NCT00003930·84 enrolled

Treatment2 trials

Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS

Completed·AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections·Phase 3·NCT01435018·334 enrolled

Drug Eluting Balloon (DEB) vs Plain Old Balloon Angioplasty (POBA) in the Treatment of Failing Dialysis Access

Completed·SSkane University Hospital·N/A·NCT05173857·42 enrolled

Esophageal Squamous Cell Carcinoma2 trials

A Study of Toripalimab Combined With Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma.

Suspended·ZZhejiang Cancer Hospital·Phase 2·NCT04084158·100 enrolled

Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma

Enrolling by invitation·TThe First Affiliated Hospital with Nanjing Medical University·N/A·NCT06048926·30 enrolled

Gastroesophageal Junction Adenocarcinoma2 trials

LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma

Not yet recruiting·LLaNova Medicines Limited·Phase 3·NCT07362186·400 enrolled

DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy

Recruiting·RRemeGen Co., Ltd.·Phase 2/3·NCT06221748·90 enrolled

Advanced Malignant Solid Tumors2 trials

A Study of WJ05129 in Advanced Malignant Solid Tumors

Terminated·SSuzhou Junjing BioSciences Co., Ltd.·Phase 1/2·NCT05326035·26 enrolled

Tirapazamine, Carboplatin, and Paclitaxel in Treating Patients With Advanced Malignant Solid Tumors

Completed·—·Phase 1·NCT00005078·44 enrolled

Esophageal Carcinoma1 trial

Phase II Trial for Patients With Loco-Regional Esophageal Carcinoma

Terminated·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT00570531·6 enrolled

Anal Carcinoma1 trial

Efficacy Study of Chemoradiotherapy With or Without Paclitaxel in Squamous-cell Anal Carcinoma Patients

Unknown status·—·Phase 3·NCT02526953·314 enrolled

Hematologic Malignancies1 trial

A Phase 1, Dose Escalation Study to Assess the Safety and Tolerability of ASP9853 With Either Docetaxel or Paclitaxel in Patients With Advanced Non-hematologic Malignancies

Terminated· Astellas logo

Astellas·Phase 1·NCT01705483·21 enrolled

Efficacy and Safety1 trial

Efficacy and Safety of Bevacizumab (Avastin®) Combined to Weekly Paclitaxel Followed by Bevacizumab (Avastin®) Alone in Patients With Relapsed Ovarian Sex-cord Stromal Tumours (ALIENOR)

Completed·AARCAGY/ GINECO GROUP·Phase 2·NCT01770301·60 enrolled

Angiosarcoma1 trial

Phase I Study of TH1 Dendritic Cell Immunotherapy for the Treatment of Cutaneous Angiosarcoma

Withdrawn·MM.D. Anderson Cancer Center·Phase 1·NCT05799612

Fallopian Tube1 trial

Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Persistent or Recurrent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT01468909·106 enrolled

Anal Cancer1 trial

International Multicentre Study in Advanced Anal Cancer Comparing Cisplatin Plus 5 FU vs Carboplatin Plus Weekly Paclitaxel

Unknown status·RRoyal Marsden NHS Foundation Trust·Phase 2·NCT02051868·80 enrolled

Pancreatic Cancer1 trial

Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00031694·19 enrolled

Brain Cancer1 trial

Combination Chemotherapy for Patients With Brain Cancer

Completed·—·Phase 2·NCT00002814·20 enrolled

Carboplatin1 trial

Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC

Unknown status·SSamsung Medical Center·Phase 3·NCT03991403·228 enrolled

Gastroesophageal Junction1 trial

Lapatinib With Carboplatin and Paclitaxel in Esophagus and Gastroesophageal Junction (GEJ)

Terminated·—·Phase 1/2·NCT01395537·13 enrolled

Neoadjuvant Therapy1 trial

A Study of Bevacizumab (Avastin) in Neoadjuvant Therapy in Participants With International Federation of Gynecology and Obstetrics (FIGO) Stage IIIC/IV Ovarian, Tubal, or Peritoneal Cancer, Initially Unresectable

Completed· Roche logo

Roche·Phase 2·NCT01739218·99 enrolled

Pembrolizumab1 trial

A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC

Recruiting·EEikon Therapeutics·Phase 2·NCT06246110·70 enrolled

Recurrent or Metastatic1 trial

Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal Cancer

Unknown status·EECOG-ACRIN Cancer Research Group·Phase 2·NCT02560298·91 enrolled

ESS1 trial

Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols

Completed· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 1·NCT04299880·7 enrolled

Advanced Cancers1 trial

Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT00798252·111 enrolled

Histone Deacetylase Inhibitor1 trial

Safety, Tolerability and Pharmacokinetics of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy

Completed·NNewVac LLC·Phase 1·NCT02728492·51 enrolled

Advanced Head and Neck Cancer1 trial

Combination Chemotherapy in Treating Patients With Advanced Head and Neck Cancer

Completed·EEastern Cooperative Oncology Group·Phase 3·NCT00002888

Peritoneal Carcinomatosis1 trial

Oxaliplatin and Paclitaxel Plus Bevacizumab in Advanced Peritoneal Carcinomatosis

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00491855·3 enrolled

Metastatic Prostate Cancer1 trial

Paclitaxel and Bryostatin 1 in Treating Patients With Metastatic Prostate Cancer

Completed·UUniversity of Maryland, Baltimore·Phase 2·NCT00005028·46 enrolled

Recurrent Head and Neck Cancer1 trial

Paclitaxel, Cisplatin, and Filgrastim Combined With Radiation Therapy in Treating Patients With Locally Recurrent Head and Neck Cancer

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 2·NCT00005087·105 enrolled

Intravenous1 trial

Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel

Terminated· Bayer logo

Bayer·Phase 1·NCT02138812·69 enrolled

Induction Chemotherapy1 trial

Induction Chemotherapy Using Paclitaxel, Carboplatin, CPT-11 With Pegfilgrastim

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT00280787·24 enrolled

AIN1 trial

Pembro+Chemo in Brain Mets

Terminated·—·Phase 2·NCT04964960·3 enrolled

Advanced or Metastatic Solid Tumor1 trial

A Study of CTX-009 (ABL001) in Combination With Irinotecan or Paclitaxel in Advanced or Metastatic Solid Tumor Patients

Terminated·HHandok Inc.·Phase 1/2·NCT04492033·41 enrolled

Metastatic Urothelial Cancer1 trial

A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer

Recruiting·SShanghai Miracogen Inc.·Phase 3·NCT05754853·290 enrolled

First Line Therapy1 trial

Paclitaxel Micelles for Injection / Paclitaxel Injection in Combination With Cisplatin for First-line Therapy of Advanced NSCLC

Unknown status·SShanghai Yizhong Pharmaceutical Co., Ltd.·Phase 3·NCT02667743·454 enrolled

Urothelial Carcinoma1 trial

A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma

Recruiting· Shanghai Hengrui Pharmaceutical Co., Ltd. logo

Shanghai Hengrui Pharmaceutical Co., Ltd.·Phase 3·NCT06738251·402 enrolled

Phase II Clinical Study1 trial

A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]

Recruiting·NNanjing Leads Biolabs Co.,Ltd·Phase 2·NCT07331155·110 enrolled

Physical Activity1 trial

Investigating Paclitaxel Toxicity in Breast Cancer: the Roles of Physical Activity and Body Composition.

Recruiting·UUniversitair Ziekenhuis Brussel··NCT06387901·40 enrolled

Advanced Solid Tumor1 trial

Dose Escalation and Pharmacokinetic Study of Paclitaxel Liposome Injection in Treating Patients With Advanced Solid Tumor After Failure From Conventional Treatments

Unknown status·UUnknown Sponsor·Phase 4·NCT01994031·36 enrolled

Locally Advanced1 trial

Combination Chemotherapy in Treating Patients With Unresectable Locally Advanced or Metastatic Stomach Cancer

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00006081·37 enrolled

Nasopharyngeal Carcinoma1 trial

Toripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal Carcinoma

Not yet recruiting·—·Phase 2·NCT07136519·30 enrolled

Recurrent1 trial

Drug Eluting Balloon Angioplasty for Recurrent Cephalic Arch Stenosis in Dialysis Fistulas

Terminated·SShaare Zedek Medical Center·Phase 2/3·NCT02368197·13 enrolled

Malignant Tumors1 trial

Recombinant Human Endostatin Adenovirus Combined With Chemotherapy for Advanced Head and Neck Malignant Tumors

Unknown status·RRenmiao Zhang·Phase 2·NCT02283489·180 enrolled

Merkel Cell Carcinoma1 trial

F16IL2 Plus Paclitaxel in Metastatic Merkel Cell Carcinoma

Terminated·PPhilogen S.p.A.·Phase 2·NCT02054884·13 enrolled

Head and Neck Squamous Cell Carcinoma1 trial

A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)

Recruiting·LLyvgen Biopharma Holdings Limited·Phase 2·NCT06378177·64 enrolled

Pancreatic Ductal Adenocarcinoma1 trial

Gemcitabine and Paclitaxel vs Gemcitabine Alone After FOLFIRINOX Failure in Metastatic Pancreatic Ductal Adenocarcinoma

Completed·UUNICANCER·Phase 3·NCT03943667·211 enrolled

Regulatory

FDA Approval Timeline[5]

Dec 29, 1992

TAXOL

NDA NDA020262

Jan 7, 2005

ABRAXANE

NDA NDA021660

Jul 27, 2022

PACLITAXEL

NDA NDA211875

May 11, 2023

PACLITAXEL

NDA NDA216338

Sources

References

[1]
ClinicalTrials.gov — 2239 trial records for paclitaxel. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Taxol drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — paclitaxel compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for paclitaxel. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA216338). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Taxol. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Teva company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Tubulin Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Teva

Patent Landscape[6]

Patent Cliff

Feb 13, 2027

Earliest patent expiration — generic entry possible after this date

Patent #Expires

8268348Feb 21, 2026

9101543Feb 21, 2026

7758891Feb 21, 2026

8034375Aug 13, 2026

8268348*PEDAug 21, 2026

9 more patents

9101543*PEDAug 21, 2026

7758891*PEDAug 21, 2026

8034375*PEDFeb 13, 2027

9597409Mar 4, 2032

9393318Mar 4, 2032

9393318*PEDSep 4, 2032

9597409*PEDSep 4, 2032

9511046Jan 12, 2034

9511046*PEDJul 12, 2034